Literature DB >> 24993455

FDG PET/CT methodology for evaluation of treatment response in lymphoma: from "graded visual analysis" and "semiquantitative SUVmax" to global disease burden assessment.

Sandip Basu1, Habib Zaidi, Ali Salavati, Søren Hess, Poul Flemming Høilund Carlsen, Abass Alavi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24993455     DOI： 10.1007/s00259-014-2826-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  11 in total

1.  Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010.

Authors:  Michel Meignan; Andrea Gallamini; Corinne Haioun; Aaron Polliack
Journal:  Leuk Lymphoma       Date:  2010-11-15

2.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Authors:  Martin Hutchings; Annika Loft; Mads Hansen; Lars Møller Pedersen; Thora Buhl; Jesper Jurlander; Simon Buus; Susanne Keiding; Francesco D'Amore; Anne-Marie Boesen; Anne Kiil Berthelsen; Lena Specht
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Early FDG-PET response-adapted risk stratification and further therapeutic decision-making in lymphoma: will this replace the established prognostic indices and be the standard-of-care in clinical management?

Authors:  Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-28       Impact factor: 9.236

4.  Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.

Authors:  Cédric Rossi; Salim Kanoun; Alina Berriolo-Riedinger; Inna Dygai-Cochet; Olivier Humbert; Caroline Legouge; Marie Lorraine Chrétien; Jean-Noel Bastie; François Brunotte; René-Olivier Casasnovas
Journal:  J Nucl Med       Date:  2014-02-24       Impact factor: 10.057

5.  Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus.

Authors:  Michel Meignan; Andrea Gallamini; Emmanuel Itti; Sally Barrington; Corinne Haioun; Aaron Polliack
Journal:  Leuk Lymphoma       Date:  2012-04-23

6.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Authors:  Malik E Juweid; Sigrid Stroobants; Otto S Hoekstra; Felix M Mottaghy; Markus Dietlein; Ali Guermazi; Gregory A Wiseman; Lale Kostakoglu; Klemens Scheidhauer; Andreas Buck; Ralph Naumann; Karoline Spaepen; Rodney J Hicks; Wolfgang A Weber; Sven N Reske; Markus Schwaiger; Lawrence H Schwartz; Josee M Zijlstra; Barry A Siegel; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

7.  Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET.

Authors:  Arnold Berkowitz; Sandip Basu; Shyam Srinivas; Shrinkanthan Sankaran; Stephen Schuster; Abass Alavi
Journal:  Nucl Med Commun       Date:  2008-06       Impact factor: 1.690

8.  Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.

Authors:  Tae Min Kim; Jin Chul Paeng; In Kook Chun; Bhumsuk Keam; Yoon Kyung Jeon; Se-Hoon Lee; Dong-Wan Kim; Dong Soo Lee; Chul Woo Kim; June-Key Chung; Il Han Kim; Dae Seog Heo
Journal:  Cancer       Date:  2012-12-04       Impact factor: 6.860

9.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Authors:  Andrea Gallamini; Martin Hutchings; Luigi Rigacci; Lena Specht; Francesco Merli; Mads Hansen; Caterina Patti; Annika Loft; Francesco Di Raimondo; Francesco D'Amore; Alberto Biggi; Umberto Vitolo; Caterina Stelitano; Rosario Sancetta; Livio Trentin; Stefano Luminari; Emilio Iannitto; Simonetta Viviani; Ivana Pierri; Alessandro Levis
Journal:  J Clin Oncol       Date:  2007-07-23       Impact factor: 44.544

10.  How to study optimal timing of PET/CT for monitoring of cancer treatment.

Authors:  Werner Vach; Poul Flemming Høilund-Carlsen; Barbara Malene Fischer; Oke Gerke; Wolfgang Weber
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-07-20
View more
  14 in total

1.  PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues.

Authors:  Oke Gerke; Karen Ehlers; Edith Motschall; Poul Flemming Høilund-Carlsen; Werner Vach
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

2.  Quantitative analysis of image metrics for reduced and standard dose pediatric 18F-FDG PET/MRI examinations.

Authors:  Pietro Zucchetta; Marco Branchini; Alessandra Zorz; Valentina Bodanza; Diego Cecchin; Marta Paiusco; Franco Bui
Journal:  Br J Radiol       Date:  2019-01-23       Impact factor: 3.039

3.  Pretreatment volumetric parameters of FDG-PET predict the survival after Yttrium-90 radio-embolization in metastatic liver disease.

Authors:  Siavash Mehdizadeh Seraj; Mahdi Zirakchian Zadeh; Thomas J Werner; Hongming Zhuang; Terence Gade; Abass Alavi; Stephen J Hunt
Journal:  Am J Nucl Med Mol Imaging       Date:  2019-10-15

4.  Correction for Partial Volume Effect Is a Must, Not a Luxury, to Fully Exploit the Potential of Quantitative PET Imaging in Clinical Oncology.

Authors:  Abass Alavi; Thomas J Werner; Poul Flemming Høilund-Carlsen; Habib Zaidi
Journal:  Mol Imaging Biol       Date:  2018-02       Impact factor: 3.488

5.  Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing/refractory non-hodgkin lymphoma following radioimmunotherapy.

Authors:  Raheleh Taghvaei; Mahdi Zirakchian Zadeh; Reza Sirous; Sara Pourhassan Shamchi; William Y Raynor; Siavash Mehdizadeh Seraj; Mateen Moghbel; Shiyu Wang; Thomas J Werner; Hongming Zhuang; Abass Alavi
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-12-20

Review 6.  Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions).

Authors:  Navid Hasani; Sriram S Paravastu; Faraz Farhadi; Fereshteh Yousefirizi; Michael A Morris; Arman Rahmim; Mark Roschewski; Ronald M Summers; Babak Saboury
Journal:  PET Clin       Date:  2022-01

Review 7.  Emerging role of 18F-FDG PET/CT in Castleman disease: a review.

Authors:  Benjamin Koa; Austin J Borja; Mahmoud Aly; Sayuri Padmanabhan; Joseph Tran; Vincent Zhang; Chaitanya Rojulpote; Sheila K Pierson; Mark-Avery Tamakloe; Johnson S Khor; Thomas J Werner; David C Fajgenbaum; Abass Alavi; Mona-Elisabeth Revheim
Journal:  Insights Imaging       Date:  2021-03-11

Review 8.  State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET.

Authors:  Thomas Carlier; Clément Bailly
Journal:  Front Med (Lausanne)       Date:  2015-03-23

9.  18F-fluoro-deoxy-glucose positron emission tomography combined with computed tomography can reliably rule-out infection and cancer in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis suspected of disease relapse.

Authors:  Evan C Frary; Søren Hess; Oke Gerke; Helle Laustrup
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

10.  Global disease score (GDS) is the name of the game!

Authors:  Poul F Høilund-Carlsen; Lars Edenbrandt; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-10       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.